Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,accountsPayable,shortTermInvestments,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,otherCashflowsFromInvestingActivities,netBorrowings,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,currency,exchange,marketCap,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,market,exchangeDataDelayedBy,shortName,regularMarketPreviousClose,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,ENTBF,7073224.0,54039300,601745,,-2883637,,-2883637,1651805,0,-3166819,-3166819,,,,,,0,0,3166819,0,283182,,-2883637,-2883637,4789204.0,171557.0,11862428.0,12033985.0,17891525.0,-7543156.0,1514059.0,5022241.0,171557.0,1514059.0,6087.0,6438271.0,800423.0,91793.0,154634.0,,-405760.0,-625435.0,-917.0,4951209.0,166757.0,4951209.0,2235235.0,-2715057.0,89293.0,-3678.0,541643.0,-1336.0,,,6266714.0,en-US,US,EQUITY,False,Delayed Quote,0.3,1630505742,-0.0010999739,0.323,0.323,0.3,50761,USD,PNK,16211791,-14400000,False,False,REGULAR,4,-0.36531848,0.3 - 0.323,us_market,0,ENTHEON BIOMEDICAL CORP,0.3011,finmb_667062728,Other OTC,Entheon Biomedical Corp.,CAD,49532,40466,0.07700001,0.3452915,0.223 - 1.5,-1.2,-0.8,0.223,1.5,1605139200,0.26383334,0.036166668,0.13708149,0.40225363,-0.102253616,-0.25420186,15,America/New_York,EDT,,,,1.5,0.223,0.2638,0.4023,49.53k,40.47k,54.04M,,47.65M,9.35%,2.29%,,,,,,,,,,,0.00%,"Nov 11, 2020",,,,"Nov 29, 2020","Feb 27, 2021",0.00%,0.00%,,,,,,,-4.37M,-6.9M,,,5.02M,0.09,,,37.53,,-5.23M,,Value,V3B 6B4,Healthcare,3,"Entheon Biomedical Corp., a biotechnology research and drug development company, engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company is headquartered in Coquitlam, Canada.",Coquitlam,604 562 3932,BC,1609372800,Canada,http://entheonbiomedical.com,86400,3030 Lincoln Avenue,Biotechnology,Suite 211
t-1,ENTBF,3744880.0,54039300,442560,,-3290429,,-3290429,78592,0,-521751,-521751,,,,,,0,0,521751,0,-2768678,,-3290429,-3290429,,728192.0,3744880.0,4473072.0,7146773.0,-4659519.0,1257626.0,2787006.0,728192.0,1257626.0,6309.0,4404433.0,62330.0,76433.0,723622.0,50000.0,-147680.0,-211844.0,1160776.0,1496377.0,-917107.0,1496377.0,946394.0,-1710759.0,599.0,-65998.0,2774020.0,4074.0,150077.0,,3676241.0,en-US,US,EQUITY,False,Delayed Quote,0.3,1630505742,-0.0010999739,0.323,0.323,0.3,50761,USD,PNK,16211791,-14400000,False,False,REGULAR,4,-0.36531848,0.3 - 0.323,us_market,0,ENTHEON BIOMEDICAL CORP,0.3011,finmb_667062728,Other OTC,Entheon Biomedical Corp.,CAD,49532,40466,0.07700001,0.3452915,0.223 - 1.5,-1.2,-0.8,0.223,1.5,1605139200,0.26383334,0.036166668,0.13708149,0.40225363,-0.102253616,-0.25420186,15,America/New_York,EDT,,,,1.5,0.223,0.2638,0.4023,49.53k,40.47k,54.04M,,47.65M,9.35%,2.29%,,,,,,,,,,,0.00%,"Nov 11, 2020",,,,"Nov 29, 2020","Feb 27, 2021",0.00%,0.00%,,,,,,,-4.37M,-6.9M,,,5.02M,0.09,,,37.53,,-5.23M,,Value,V3B 6B4,Healthcare,3,"Entheon Biomedical Corp., a biotechnology research and drug development company, engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company is headquartered in Coquitlam, Canada.",Coquitlam,604 562 3932,BC,1609372800,Canada,http://entheonbiomedical.com,86400,3030 Lincoln Avenue,Biotechnology,Suite 211
t-2,ENTBF,1992279.0,54039300,442560,,-350663,,-350663,412562,0,-413270,-413270,,,,,,0,0,413270,0,62607,,-350663,-350663,,44115.0,1992279.0,2036394.0,3357741.0,-1369090.0,3628.0,1840612.0,44115.0,3628.0,10982.0,1924880.0,100532.0,26572.0,44115.0,52077.0,-147680.0,0.0,1160776.0,1496377.0,-917107.0,1496377.0,946394.0,-1710759.0,599.0,-65998.0,2774020.0,4074.0,150077.0,,1880765.0,en-US,US,EQUITY,False,Delayed Quote,0.3,1630505742,-0.0010999739,0.323,0.323,0.3,50761,USD,PNK,16211791,-14400000,False,False,REGULAR,4,-0.36531848,0.3 - 0.323,us_market,0,ENTHEON BIOMEDICAL CORP,0.3011,finmb_667062728,Other OTC,Entheon Biomedical Corp.,CAD,49532,40466,0.07700001,0.3452915,0.223 - 1.5,-1.2,-0.8,0.223,1.5,1605139200,0.26383334,0.036166668,0.13708149,0.40225363,-0.102253616,-0.25420186,15,America/New_York,EDT,,,,1.5,0.223,0.2638,0.4023,49.53k,40.47k,54.04M,,47.65M,9.35%,2.29%,,,,,,,,,,,0.00%,"Nov 11, 2020",,,,"Nov 29, 2020","Feb 27, 2021",0.00%,0.00%,,,,,,,-4.37M,-6.9M,,,5.02M,0.09,,,37.53,,-5.23M,,Value,V3B 6B4,Healthcare,3,"Entheon Biomedical Corp., a biotechnology research and drug development company, engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company is headquartered in Coquitlam, Canada.",Coquitlam,604 562 3932,BC,1609372800,Canada,http://entheonbiomedical.com,86400,3030 Lincoln Avenue,Biotechnology,Suite 211
t-3,ENTBF,42174.0,54039300,110964,,-368847,,-368847,234505,0,-345847,-345847,,,,,,0,0,345847,0,-23000,,-368847,-368847,,,42174.0,,,,,,,,,,,,,,-198000.0,44868.0,-203492.0,842603.0,-15914.0,845632.0,314430.0,-324681.0,378.0,-8166.0,23000.0,-5492.0,150077.0,-3029.0,,en-US,US,EQUITY,False,Delayed Quote,0.3,1630505742,-0.0010999739,0.323,0.323,0.3,50761,USD,PNK,16211791,-14400000,False,False,REGULAR,4,-0.36531848,0.3 - 0.323,us_market,0,ENTHEON BIOMEDICAL CORP,0.3011,finmb_667062728,Other OTC,Entheon Biomedical Corp.,CAD,49532,40466,0.07700001,0.3452915,0.223 - 1.5,-1.2,-0.8,0.223,1.5,1605139200,0.26383334,0.036166668,0.13708149,0.40225363,-0.102253616,-0.25420186,15,America/New_York,EDT,,,,1.5,0.223,0.2638,0.4023,49.53k,40.47k,54.04M,,47.65M,9.35%,2.29%,,,,,,,,,,,0.00%,"Nov 11, 2020",,,,"Nov 29, 2020","Feb 27, 2021",0.00%,0.00%,,,,,,,-4.37M,-6.9M,,,5.02M,0.09,,,37.53,,-5.23M,,Value,V3B 6B4,Healthcare,3,"Entheon Biomedical Corp., a biotechnology research and drug development company, engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company is headquartered in Coquitlam, Canada.",Coquitlam,604 562 3932,BC,1609372800,Canada,http://entheonbiomedical.com,86400,3030 Lincoln Avenue,Biotechnology,Suite 211
